Encyclopedia of lung cancer /
Saved in:
| Imprint: | New York : Nova Biomedical, [2015] |
|---|---|
| Description: | 1 online resource. |
| Language: | English |
| Series: | Cancer etiology, diagnosis, and treatments Cancer etiology, diagnosis, and treatments. |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11249302 |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | 11249302 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 150706s2015 nyua ob 001 0 eng | ||
| 005 | 20240620204848.0 | ||
| 010 | |a 2020687197 | ||
| 020 | |a 9781634834728 |q ebook | ||
| 020 | |a 1634834720 | ||
| 020 | |z 1634834712 |q hbk. | ||
| 020 | |z 9781634834711 |q hbk. | ||
| 035 | |a (OCoLC)926705916 | ||
| 035 | 9 | |a (OCLCCM-CC)926705916 | |
| 040 | |a DLC |b eng |e rda |c DLC |d N$T |d YDXCP |d OCLCF |d EBLCP |d AGLDB |d VTS |d AU@ |d STF |d M8D |d VLY |d OCLCO | ||
| 049 | |a MAIN | ||
| 050 | 0 | 0 | |a RC280.L8 |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 245 | 0 | 0 | |a Encyclopedia of lung cancer / |c Andrea Hawkins, editor. |
| 264 | 1 | |a New York : |b Nova Biomedical, |c [2015] | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Cancer etiology, diagnosis, and treatments | |
| 504 | |a Includes bibliographical references and index. | ||
| 588 | |a Description based on print version record. | ||
| 505 | 0 | |a ENCYCLOPEDIA OF LUNG CANCER ; ENCYCLOPEDIA OF LUNG CANCER ; Library of Congress Cataloging-in-Publication Data; CONTENTS ; PREFACE ; Chapter 1 THERAPEUTIC ANTIBODIES IN NON-SMALL CELL LUNG CANCER: AN OVERVIEW AND FUTURE DIRECTIONS ; ABSTRACT ; INTRODUCTION ; 1. THERAPEUTIC ANTIBODIES IN CANCER: RATIONALE ; 1.1. Structure of Monoclonal Antibodies (Mab) ; 1.2. History of Therapeutic mAbs ; 1.3. Pharmacodynamic ; 1.3.1. Fab Domain ; 1.3.2. Fc Domain ; 1.3.3. Conjugated or Armed mAbs ; 1.4. Pharmacokinetics of mAbs ; 1.4.1. FcRn Receptor ; 1.4.2. Administration and Absorption | |
| 505 | 8 | |a 1.4.3. Distribution 1.4.4. Metabolism and Elimination ; 1.4.5. Engineered IgG and Their Pharmacokinetics ; 1.4.6. Other Factors Influencing the Pharmacokinetics of mAbs ; 1.5. Immunogenicity and Safety of mAbs ; 1.5.1. Anti-Antibody Response (AAR) ; 1.5.2. Cytokine Release Syndrome (CRS) ; 2. THERAPEUTIC ANTIBODIES IN NON SMALL CELL LUNG CANCER (NSCLC): PRE-CLINICAL AND CLINICAL STUDIES ; 2.1. Anti-VEGF Antibodies ; 2.1.1. Vascular Epidermal Growth Factor (VEGF) and NSCLC ; 2.1.2. Bevacizumab ; 2.1.2.1. Preclinical Studies with Bevacizumab ; 2.1.2.2. Pharmacokinetic | |
| 505 | 8 | |a 2.1.3. Clinical Trials of Bevacizumab Combined with Chemotherapy 2.1.3.1. Phase II Clinical Trial ; 2.1.3.2. Phase II Clinical Trial in Squamous Non Small Cell Lung Cancer ; 2.1.3.3. Phase III Clinical Trials in Non Squamous Non Small Cell Lung Cancer ; 2.1.3.4. Phase IV Clinical Trials in Non Squamous Non Small Cell Lung Cancer ; 2.1.3.5. Bevacizumab As Maintenance Therapy: Current Concepts ; 2.1.3.6. Bevacizumab As Maintenance Therapy: Future Directions; 2.1.4.Clinical Trials of Bevacizumab Combined with Targeted Therapy ; 2.1.4.1.Erlotinib ; 2.1.4.1.1. Phase I and II Trials | |
| 505 | 8 | |a 2.1.4.1.2. Phase III Trial 2.1.4.1.3. Erlotinib and Bevacizumab: Future Directions ; 2.1.4.2. Sunitinib ; 2.1.5. Clinical Trials of Bevacizumab in Elderly Patients ; 2.1.6. Predictive Markers ; 2.1.6.1. Current Concepts ; 2.1.6.2. Future Directions ; 2.1.7. Anti-VEGFR2: Ramucirumab ; 2.1.8. Fab Anti-VEGF: Ranibizumab ; 2.2. Anti-HER Antibodies ; 2.2.1. EGFR and Signaling Pathways ; 2.2.1.1. ERBB1 (EGFR) ; 2.2.1.2. ERBB2 (HER2) ; 2.2.2. Cetuximab: Anti-EGFR Antibody ; 2.2.2.1. Pre-Clinical Studies ; 2.2.2.2. Preclinical Studies on the Pulmonary Administered of Cetuximab | |
| 505 | 8 | |a 2.2.2.3. Pharmacokinetic 2.2.2.4. Clinical Trials of Cetuximab Combined with Chemotherapy ; 2.2.2.4.1. Phase I/II ; 2.2.2.4.1.1. First Line Therapy ; 2.2.2.4.1.2. Second Line Therapy ; 2.2.2.4.1.3. Bronchioloalveolar Carcinoma ; 2.2.2.4.2. Phase III ; 2.2.2.4.3. Cetuximab and Other Targeted Therapies ; 2.2.2.4.3.1. Anti-EGFR Tyrosine Kinase Inhibitor ; 2.2.2.4.3.2. Bortezomib ; 2.2.2.4.4. Cetuximab and Radiotherapy ; 2.2.2.4.5. Cetuximab and Predictive Markers ; 2.2.3. Anti-EGFR: Matuzumab ; 2.2.4. Anti-EGFR: Nimotuzumab ; 2.2.5. Anti-EGFR: Panitumumab; 2.2.6. Anti-EGFR: Necitumumab | |
| 650 | 0 | |a Lungs |x Cancer. |0 http://id.loc.gov/authorities/subjects/sh85078900 | |
| 650 | 2 | |a Lung Neoplasms |x diagnosis. | |
| 650 | 2 | |a Lung Neoplasms |x therapy. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Lungs |x Cancer. |2 fast |0 (OCoLC)fst01003756 | |
| 655 | 0 | |a Electronic books. | |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a Hawkins, Andrea |c (Editor), |e editor. |0 http://id.loc.gov/authorities/names/nb2016003084 | |
| 776 | 0 | 8 | |i Print version: |t Encyclopedia of lung cancer |d New York : Nova Biomedical, [2015] |z 1634834712 (hbk.) |w (DLC) 2015945689 |
| 830 | 0 | |a Cancer etiology, diagnosis, and treatments. |0 http://id.loc.gov/authorities/names/n2009183163 | |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i 954bddae-3035-514c-a513-f14db6832447 |s 6f1d44ab-6720-5cd6-85fd-dddb0de52a8a |
| 928 | |t Library of Congress classification |a RC280.L8 |l Online |c UC-FullText |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=1084512 |z eBooks on EBSCOhost |g ebooks |i 12431162 | ||